News & Events

San Jose, CA, United States - AirXpanders, Inc. (ASX: AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today announced it has signed a four (4) year distribution agreement with Spiran Pty Ltd. ("Spiran") appointing Spiran as the exclusive distributor of its AeroForm Tissue Expander System in the Australian market effective July 1, 2018. 

Spiran is headquartered in Adelaide, South Australia, with sales and marketing personnel based in all major Australia cities. Spiran is the Australia-wide distributor of a suite of aesthetic and surgical products focused on breast surgery, including Establishment Lab's Motiva® breast implant.

"Spiran is a well-established distributor in the Australian market with complementary product offerings through similar sales channels suitable for AeroForm," commented Scott Murcray, interim CEO. "We are delighted to have Spiran as our distribution partner in Australia ensuring physicians and women in Australia have full access to AeroForm while reducing the costs associated with the AirXpanders' direct presence there."

Adrian Magnera, Chief Executive Officer of Spiran, added, "Spiran's mission is to bring highly innovative products to Australian patients and plastic surgeons and we are excited to add AeroForm to the next-generation suite of medical devices we distribute."

- ENDS -

Company Scott Murcray
Interim President & CEO
Tel: +1 (650)-282-8106
Email: [email protected]

Investor relations
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722 / + 61 (0)401018828
Email: [email protected]

About AirXpanders
Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The Company's AeroForm Tissue Expander System, is used in patients undergoing twostage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.
AirXpanders is a publicly listed Company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA de novo marketing authorization in 2016, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, but are not limited to, the adequacy of Spiran as a distributor in Australia, and the ability to recognize efficiency as a result of restructuring our sales model in Australia.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on May 2, 2018, including under the caption "Risk Factors," as well as other periodic reports filed with the SEC from time to time. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.

For more information, refer to the Company's website at www.airxpanders.com.